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Summary 
~/8 T  cells can be grouped into discrete subsets based upon their expression of T  cell receptor 
(TCR) variable (V) region families, their tissue distribution, and their specificity. V~2 + T  cells 
constitute the majority of~/8 T  cells in peripheral blood whereas V81 + T  cells reside preferen- 
tially in skin epithelium and in the intestine. ~/~ T  cells are envisioned as first hne host defense 
mechanisms capable of providing a source of immune effector T  cells and immunomodulating 
cytokines such as interleukin (IL) 4 or interferon (IFN) % We describe here the fine specificity 
of three distinct ~/~+ tumor-infiltrating lymphocytes (TIL) obtained from patients with primary 
or metastatic colorectal cancer, that could be readily expanded in vitro in the presence oflL-l~ 
and IL-7. Irrespective of donor, these individual ~/8 T  cells exhibited a similar pattern of reac- 
tivity defined by recognition ofautologous and allogeneic colorectal cancer cells, renal cell can- 
cer, pancreatic cancer, and a freshly isolated explant from human intestine as measured by cy- 
tolytic T  cell responses and by IFN-~/release. In contrast, tumors of akemate histologies were 
not lysed, including lung cancer, squamous cell cancer, as well as the natural/lymphocyte-acti- 
vated killer cell-sensitive hematopoietic cell lines T2, CIR, or Daudi. The cell hne K562 was 
only poorly lysed when compared with colorectal cancer targets. Target cell reactivity medi- 
ated by V8I + T  cells was partially blocked with Abs directed against  the TCR, the [32 or [37 
integrin chains, or fibronectin receptor. Marker analysis using flow cytometry revealed that all 
three ~  T  cell lines exhibit a similar phenotype. Analysis of the ~/8 TCR junctional suggested 
exclusive usage of the V81/D~3/J81  TCtk segments with extensive (~<29 bp) N/P region di- 
versity. T  cell recognition of target cells did not appear to be major histocompatibility complex 
restricted or to be correlated with target cell expression of heat-shock proteins. Based on the 
ability of some epithehal tumors, including colorectal, pancreatic, and renal cell cancers to ef- 
fectively cold target inhibit the lysis of colorectal cancer cell lines by these V8I + T  cell lines, 
we suggest that intestinal V~I + T  cells are capable of recognizing cell surface Ag(s) shared by 
tumors of epithehal origin. 
T 
wo  distinct  populations  of ~/8+ TCK-bearing  cells 
have been previously characterized based on their ex- 
pression of distinct TCtk V gene segments and their unique 
tissue distribution. The dominant ~/8+ T  cell population in 
the  peripheral  circulation is  defined by  coexpression of 
the V~2  and the V~/9 TCK  (1,  2)  segments,  constituting 
70-90% of the ~/~+ T  subsets  in PBL, and representing 
5-10% of all TCK  + peripheral T lymphocytes. A different, 
far less frequent, ~/8  + T  cell population in PBL is detected 
by  the  mAb  ~TCS-1  (3)  recognizing  the  V81/J81/J~2 
TCR  (4).  This particular subpopulation  constitutes  only 
5-10% of the ~/8 T  cell population in human PBL, but it 
represents the majority of',/8 T  lymphocytes found in the 
oral  and  intestinal  epithelia  (5-9).  The  TCtk  V~2/V~/9 
predominance in PBL is thought to reflect an Ag-driven 
expansion potentially involving the superantigen staphylo- 
coccal  enterotoxin A  (10),  isopentyl pyrophosphate,  and 
related prenyl pyrophosphate derivates, components ofmy- 
cobacterial  Ags  (11),  or  cell-derived  proteins  expressed 
upon viral infection (12).  Individual ",/8 T  cell clones have 
been previously reported to recognize MHC class I and II, 
CDlc Ags,  nonclassical minor MHC  Ags,  or heat--shock 
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region  of the  ~/~  TCR  (21)  suggests  that  the  topology of 
the  interaction  of the ~  TCR  with  MHC  Ags is  clearly 
different  from  that  observed  for oq3 §  T  cells,  suggesting 
that  the  ~/5  TCR  may be  able  to  recognize  native  (i.e., 
non-MHC  presented)  protein  Ags  (12).  This  hypothesis 
implies  that  Ag  recognition  by  ~/5 +  T  cells  may  more 
closely resemble soluble Ag recognition by Igs, rather than 
recognition of short peptide fragments presented by MHC 
molecules to off3  +  TCR.  cells  (12,  19,  20).  Whereas  some 
targets have been identified for V~2 + T  cells,  the Ags rec- 
ognized by the V81 + TCR  subset are unknown. Exclusive 
expansion  of this  particular  subset  has been  observed in a 
variety of different diseases: V~I § T  cells are selectively ex- 
panded  in  vivo  in  the  peripheral  blood  of patients  with 
EBV or HIV infections (22-24). V81 + T  cells are also pref- 
erentially expanded in the lungs of  patients with pulmonary 
sarcoidosis and in lesions from patients infected with Myco- 
bacterium  leprae  (25),  in  synovial  fluid  from patients  with 
rheumatoid arthritis (26, 27), in cerebospinal fluid from pa- 
tients with acute multiple sclerosis (28, 29), in intestinal le- 
sions  from patients  with  coelical  disease  (30,  31),  and  in 
acute or chronic graft rejections in heart transplant patients 
(32).  Preferential  expansion  and  cytotoxic  antitumor  re- 
sponses of the V81 + T  cell subset have been demonstrated 
in patients with tumors of epithelial  origin, including ade- 
nocarcinomas  of the  lung  (33,  34)  and,  most recently,  in 
renal  cell  cancer  (35).  Such VB1  TCR +  T  cells  exhibit  a 
characteristic recognition pattern, lysing the autologous and 
allogeneic cell lines with similar histologies (35). V~I + T  cells 
lyse,  albeit  to  a  lesser  extent,  the  NK-sensitive  celt  line 
K562, but not other NK/LAK-sensitive cell lines,  and are 
apparently not MHC  restricted  (33-35).  We report the in 
vitro expansion  of three V~I §  T  cell lines  cultured in the 
presence  of IL-1[3 and  IL-7 from tumor-infiltrating  lym- 
phocytes (TIL) derived from patients with primary or met- 
astatic  colorectal  cancer.  These  ~/~  T  cell  lines  appear  to 
recognize  common Ag(s)  shared  by colorectal,  renal  cell, 
and pancreatic cancers defined by both cytolytic T  cell re- 
activity and by IFN-'y release. These data suggest that cyto- 
toxic V81 §  T  cells  may be  critically involved in immune 
responses against cancer of epithelial origin in situ. 
Materials and Methods 
Cell Lines.  Target cell lines used in cytotoxicity or cytokine 
release assays were maintained in [kPMI-1640 supplemented with 
10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 100 
IU/ml penicillin,  and  100  p~g/ml streptomycin (GIBCO BRL, 
Gaithersburg,  MD; complete medium [CM]) unless otherwise in- 
dicated.  Short-term cultures  of freshly harvested  tumor single cell 
suspensions  from colorectal cancer patients  were  also grown in 
CM. CIR. or human EBV-transformed B cell lines (S-EBV) ex- 
pressing the muc 1 molecules have been described previously (36) 
1Abbreviations used in this paper: CM, complete medium; HFR, human fi- 
bronectin receptor; HVR, human vitronectin receptor; RT, reverse tran- 
scriptase; TIL, tumor-infiltrating lymphocyte(s). 
and  were  grown in  CM  supplemented  with  600  p.g/ml  G418 
(GIBCO BRL). The breast cancer cell line BT20 and the cell line 
U937  (MHC  class II negative),  its  MHC  class II-positive sub- 
clone I 937, the colorectal cancer cell line DLD-1, the pancreatic 
cancer cell lines  pancreas89  and pancreasQGP9  were  kind  gifts 
from Dr. O. Finn (University of Pittsburgh Medical  School). The 
colorectal cancer cell lines LS174 and SW480, the Wilms tumor cell 
line SKNEP-1, and the explant culture (passage 1) from normal 
human  intestine  (CRL7136,  HS186.lNT)  were  obtained  from 
the  American  Type  Culture  Collection  (ATCC,  R.ockville, 
MD).  The colorectal cancer cell lines  HCT116 and HT29,  the 
squamous  cell  cancer cell  lines  PCI-13 and  PCI-50  (head  and 
neck cancer),  and target cell lines Daudi, Molt-4, and K562 were 
kindly provided by Dr.  Theresa Whiteside,  University of Pitts- 
burgh Cancer Institute.  The lung cancer cell lines lung201  and 
lung89 were obtained from Dr. Steven Dobrowolski (University 
of Pittsburgh Medical School).  The melanoma cell line 526 was 
kindly provided by Dr. S.A. Rosenberg,  (National  Cancer Insti- 
tute).  The renal  cell cancer cell lines NT1973 and NT1257 and 
the  melanoma  cell  line  Mz18  were  kindly provided from Dr. 
Alex Knuth (Krankenhaus  Nordwest, Frankfurt,  Germany). 
TIL.  TIL from patients  1881  (colon adenocarcinoma), 3481 
(colon adenocarcinoma) and 7179  (colon adenocarcinoma met- 
astatic  to liver)  were  generated  as described previously (37) by 
mincing freshly  harvested  tumor,  by digestion  with  collagenase 
(Sigma Chemical Co., St. Louis, MO), and by centrifugation  over 
a  Ficoll  gradient.  The  gradient interface  was  collected,  washed 
twice, resuspended  in AIM-V medium (GIBCO BRL), supple- 
mented  with  1,000  IU/rrd  rhIL-l[3  and  1,000  IU/ml  rhlL-7 
(kindly  provided by Dr.  Michael  Widmer,  lmmunex,  Seattle, 
WA) and seeded at  5  ￿  10  s cells/ml  in  24-well tissue  culture 
plates.  TIL have  never been  restimulated  in  vitro  with  tumor. 
They were split if the cell number exceeded  1.5  ￿  106 cells/ml 
and fed with IL-11B/IL-7 containing AIM-V medium. TIL were 
tested  at  various  time  points  after  in  vitro  propagation for the 
presence  of "y5  +  T  lymphocytes by  flow  cytometry. ~/8 +  TIL 
were purified by flow cytometric cell sorting using the anti-pan- 
~/5 TCR mAb TCR51  (clone 5A6.E93; T-Cell Sciences,  Cam- 
bridge, MA; see Table 1) and the FACStar  |  (Becton Dickinson & 
Co., Mountain View, CA) and were then expanded in IL-liB/IL- 
7-containing AIM-V medium over a period of 3 too. Highly pu- 
rified ~5 + TIL were used at various  time points during extended 
culture as effector T  cells in cytotoxicity or cytokine release as- 
says, as indicated.  The purity of the respective  ~/5 T cell lines was 
determined by flow cytometric analysis before each experiment. 
"yS+-sorted  TIL lines  exhibited  a  stable  "yg+ TCR  phenotype 
(purity >98%) over the 3-too period tested. 
Cytolytic Assays.  A standard  4-h chromium release assay was 
used to assess cytolytic recognition of tumor cells by "/5 TIL lines 
1881, 3481, and 7279 using an E/T ratio of 5:1 unless otherwise 
indicated.  LAK cells were generated  using 7-d 6,000 IU IL-2- 
stimulated  PBL obtained from donor leupacks  as control effector 
cells. SlCr-labeled  target cell suspensions  were adjusted  to 0.5  ￿ 
10  s cells/ml and 100 ILl of this cell suspension  was added to indi- 
vidual assay wells in triplicate  determinations.  100 ILl of TIL ef- 
fector cells (E/T  ratio,  5:1)  were  then  added  to  experimental 
wells and plates  incubated for 4 h  at 37~  Spontaneous release 
wells  received  100  ~1 of TIL medium (AIM-V) and maximum 
release  wells received  100 ~1 of Triton X-100 (10% vol/vol in 
water).  For blocking studies,  anti-T cell reagents  (mAbs against 
TCR, anti -132 or -[37 integrin chains, or Abs against the human 
vitronectin receptor oevl33 (HVR), or the human fibronectin re- 
ceptor ot5[31 (HFR; see Table  1) were used  to pretreat effector 
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45 rain at 4~  with the respective Ab (10  p,g/104  cells) and the 
appropriate isotype controls, followed by two washing steps using 
AIM-V medium. After careful removal of the supernatant, TIL 
were resnspended in 100 ~zl AIM-V medium supplemented with 
IL-113 and IL-7 and the appropriate target cell suspensions were 
added as indicated in 100 ~1. Target single cell suspensions were 
treated  as  indicated in  blocking experiments  using  anti-MHC 
class I and II, anti-CD1, or anti- HSP Abs (see Table 1). For cold 
target inhibition assays, 100 I~1 of the SlCr-labeled target cells was 
added to individual assay wells along with 100  ~1 of the respec- 
tive cold target single cell suspension at various dilutions as indi- 
cated. T  lymphocytes were then added (effector TIL/S1Cr target 
cells  =  5:1) in a volume of 20 ~1 per assay well and a standard 
51Cr-release  assay was performed twice. 100  I~1 aliquots was har- 
vested from each well and counted in a gamma counter (Pharma- 
cia LKB). R`esults are reported as percent specific chromium re- 
lease  calculated as:  [(Experimental cpm  -  spontaneous  cpm)/ 
(Maximum cpm -  spontaneous cpm)] ￿  100. 
Cytokine Release  Assays.  Stimulator cells were irradiated (3,000 
Gy) and adjusted to 105 cells/ml in CM. 100 p~l of this single cell 
suspension were  added to  individual wells and incubated with 
100  I~1 single cell suspension containing individual ~/~ TIL lines 
(5  ￿  105 cells/ml) in AIM-V. Control wells included stimulator 
cells alone or T cells alone. After incubation at 37~  for 16 h, su- 
pematants were harvested and stored at -20~  until assayed for 
IFN~/(R&D Systems Inc., Minneapolis, MN) by ELISA accord- 
ing to the manufacturer's instructions. Sensitivity for IFN-~/is re- 
ported as 5 pg/ml in cell culture supernatants. 
Abs and Flow Cytometry.  The specificity ofmAbs or polyclonal 
antisera used in this study is listed in Table 1. The distributors were 
T-cell Sciences, Becton Dickinson &  Co.,  Coulter Corp.  (Hi- 
aleah, FL), Amac, Inc. (Westbrook, ME), Upstate Biotechnology, 
Inc.  (Lake  Placid,  NY),  Telios  (now  GIBCO  BRL):  GIBCO 
BRL,  Chemicon  (Temecula,  CA), Mizzen,  (Victoria, Canada), 
and Dako (Carpinteria, CA). The mAb w6/32  (anti-MHC class 
I) and mAb L243  (MHC  class II, DR.) were obtained from the 
ATCC  and  were  derived  as  hybridoma  culture  supematants. 
Briefly, cells were incubated for 30 min at 4~  with directly la- 
beled FITC- or PE- conjugated Ab. For some unlabeled Abs, a 
secondary reagent FITC or PE F(ab')2 anti-mouse or anti-rabbit 
IgG was used. Controls included normal mouse or rabbit IgG ob- 
tained from Becton Dickinson &  Co. prelabeled with FITC or 
PE. In each flow cytometric sample, 5,000 events were measured 
and gates were set to exclude nonviable cells. Individual samples 
were analyzed using a FACScan  |  (Becton Dickinson & Co.) flow 
cytometer using the software program Lysis II, and results are re- 
ported as percent positive-staining cells evaluated in  two-color 
flow cytometric analysis. Using single-color (FITC or PE)-based 
detection systems,  results are reported as percent positive-staining 
cells and  are  depicted as  fluorescence intensity versus  cell size 
(FSC) histograms in order to allow for the identification of po- 
tential T cell subsets demonstrating differentially dim or bright Ab 
staining. 
Template cDNA Ppreparation.  Total R.NA from 5 X 106 to 5 ￿ 
107 cells was extracted from ~/~ TIL lines, from freshly harvested 
biopsies obtained from colon cancer lesions, or from tumor-free 
mucosa  (adjacent to tumor)  obtained from patients undergoing 
surgery for  resection of colorectal cancer  at  the  University of 
Pittsburgh Medical Center or at the Veterans Administration Hos- 
pital  (Pittsburgh,  PA)  using  R`NAzol  (Biotecx,  Inc.,  Houston, 
TX) according to the method of Chomczynski and Sacchi (38). 
First strand cDNA synthesis was perfomed by heating the reac- 
tion at 37~  for 1 h, followed by 5 min at 95~  using a PCR 
thermal cycler (Perkin-Elmer Corp., Norwalk, CT).  The 40-t~1 
reaction volume contained 8 g,g of RNA in 16 b~l H20 , 8 I~l 5)< 
reaction buffer (GIBCO BRL), 4 Ixl dithiothreitol (final concen- 
tration, 10 raM), 2  ILl dNTP (dATP, dCTP, dGTP, dTTP, final 
concentration, 1 mM each), 3 ~t R`Nase inhibitor (final concentra- 
tion,  120  U),  1  ILl actinomycin D  (final  concentration, 2  Ixg), 
4 I.tl Oligo-dT random primers (final concentration, 0.8 I~g), and 
2  I~1 Moloney murine leukemia virus reverse transcriptase (RT) 
(Perkin-Elmer Corp., final concentration, 400 IU/ml). 
Amplification of TCR-specific Templates.  150  ng of cDNA was 
used in each individual PCR` reaction throughout all experiments 
and the integrity of individual cDNA samples was analyzed using 
human  [3-actin--specific  primers  (5-3';  forward:  ATTTGCG- 
GTGGACGATGGAGGGGC,  backward:  GGCATCGTCAC- 
CAACTGGGACGAC) using the temperature profile 95~  for 
denaturation, annealing for 1 min at 60~  followed by 1 min at 
72~  for extension (30 cycles). The protocol for amplification of 
V~- or V~/-specific mRNA transcripts was 95~  (2 rain for dena- 
turation) followed by 33 cycles of  94~  (1 rain), 59~  (1 min, 30 s), 
and 72~  (1  min). The primers sequences for specific V~/ or V~ 
transcripts have been previously reported elsewhere (28).  Gener- 
ally, each reaction mixture (50 I~1 vol) contained 25 Ixl H20, 5 Ixl 
PCR` 10X reaction buffer (Perkin-Elmer Co.), 8 ~1 dNTP (con- 
centration, 1.25 mM each), 5 Ixl of each primer (final concentra- 
tion,  50  pmol each primer),  1.5  txl cDNA  (150  ng), and  1  Ixl 
Taq-polymerase (Perkin-Elmer Corp.). The respective PCR. re- 
actions were run on 1.5% ethidium bromide-stained agarose gels. 
In each PCR. run, a positive control (cDNA from heat-killed My- 
cobacterium tuberculosis-stimulated PBL)  and  a  negative  control 
(PCI~ mastermix without template cDNA) were included. Prim- 
ers were synthesized at the DNA Synthesis Facility, University of 
Pittsburgh.  The  identity of individual PCP,,  products was  con- 
finned by Southern blot using internal V'y- or V~-specific prim- 
ers (data not shown). 
Sequencing of V81 + PCR Products.  V~I +  PCR  products gen- 
erated from in vitro-cultured (>98% pure) ~+  T  cell lines were 
purified from agarose gels using microfilters obtained from Milli- 
pore Corp.  (Bedford, MA) and subcloned into the TA cloning 
vector obtained from Invitrogen (San Diego, CA). Positive clones 
were randomly selected from each individual "y8 TIL line and se- 
quenced using the ABI system (Applied Biosystems, Foster City, 
CA) at the University of Pittsburgh DNA sequencing facility. 
Results 
Colorectal Cancer-derived "1'3 T  Cells Expanded  in  IL-l[3 
and IL-7 Exclusively Express the V81  TCR Segment and Pref- 
erentially Coexpress the V~/2 TCR.  Tumor-infiltrating T lym- 
phocytes were obtained from three patients with colorectal 
cancer (patients 1881: primary colon adenocarcinoma; 3481: 
primary  colon  adenocarcinoma;  7279:  colon  adenocarci- 
noma metastatic to the liver) and were cultured for 6 wk in 
IL-113  and  IL-7  (1,000  IU/ml  each)  containing  AIM-V 
medium.  Phenotypic analysis of individual (bulk)  cultures 
performed  at  day  54  revealed  10-48%  CD3+/2t~+/V~I + 
positive-staining T  cells (data not shown). ~/~+ T  cells were 
purified from TIL cultures by flow cytometric cell sorting 
at  day 54  using a  mAb  recognizing a  framework  epitope 
present on all ~/~ TCR.  Positively sorted ~  T  cells were 
expanded  in  CM  containing  IL-113  and  IL-7  for  at  least 
1683  Maeurer et al. Table 1.  List  of  Antibodies Employed  for Flow Cytometry or Blocking Experiments 
Antibody designation  Specificity  Distributor 
WT-31  Framework (pan) et11 TCR  Becton Dickinson 
SA6.E93  Framework (pan) ~/~ TCR  T-cell Diagnostics 
~TCS-1  v~1/j81/jB2 TCR segments  T-cell Diagnostics 
15D  V~2 TCR segment  T-cell Diagnostics 
7A5  V72 (V-79) TCR segment  T-cell Diagnostics 
5T-022  CDla  CD workshop Ab 
5T-024  CDlc  CD workshop Ab 
$5.2  LFA-3, CD58 ligand  Becton Dickinson 
SK3  CD4  Becton Dickinson 
SK1  CD8  Becton Dickinson 
G25.2"  CD 1  la (aL/112), LFA-1  Becton Dickinson 
D12"  CDllb (aM/112). C3bi receptor  Becton Dickinson 
SHCL-3*  CD1 lc (aX/112) C3bi,dg receptor  Becton Dickinson 
BL5  CD18, 112 chain ofintegrins  Amac 
2A3  CD25, IL-2 (TAC) receptor  Becton Dickinson 
K20  CD29, I11 chain ofintegrins  Amac 
Ber-H2  CD30, Ki-I Ag  Dako 
L-178  CD44, HCAM, homing receptor  Becton Dickinson 
2H4  CD45-RA  Coulter 
UCHL-1  CD45-RO  Becton Dickinson 
1.2B6  CD62E, ELAM-1, E-selectin  Immunotech (Marseille, France) 
Dreg 56  CD62L, MEL14-Ag, L-selectin  Immunotech 
L78  CD69, gp34/28  Becton Dickinson 
LB-2  CD54, ICAM-1  Chemicon 
133  CD80, B7.1  (CD28 ligand)  CD workshop Ab 
1331, Fun-1  CD86, B7.2 (CD28 hgand)  Pharmingen 
3Bl.18,KP43  CD94, ot11,7~, and NK subset  CD workshop Ab 
MA-ICAM2-F  CD102, ICAM-2  Endogen, Inc. (Boston, MA) 
P1  VLA-1, otl/111,  laminin  + collagen receptor  Telios 
P1E6  VLA-2, et2/111, laminin  + collagen receptor  Telios 
P1E5  VLA-3, ot3/111, collagen, fibronectin receptor  Telios 
B-5G10  VLA-4, et4/111, VCAM-1, fibronectin receptor  Upstate Biotechnology 
P1-D6  VLA-5, et5/111, fibronectin receptor  Telios 
GoH3  VLA-6, et5/111, laminin receptor  Amac 
LM142  otv (CD51), vitronectin receptor chain  Chemicon 
LM609  ecv113 (CD51/CD61) vitronectin receptor  Chemicon 
PIF6  etv115, vitronectin receptor  Chemicon 
Polyclonal antiserum, absorbed with ot5111  avb3/[35, vitronectin receptor  GIBCO BRL 
Polyclonal antiserum, absorbed with etv113/115  ot5111,  fibronectin receptor  GIBCO BRL 
HML-1  CD103, [37 integrin chain on IEL  Amac and Immunotech 
SPA804  HSP 60  Mizzen 
SPA826-2, polyclonal antiserum  HSP 68  Mizzen 
SPA810  HSP 70  Mizzen 
SPA825  HSP 75  Mizzen 
SPA811  HSP 75  Mizzen 
SPA820  HSP 73  Mizzen 
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phenotype,  which  was  documented  on a  weekly basis  by 
flow cytometric analysis.  Fig.  1 shows a characteristic flow 
cytometric analysis of sorted ~/8 + TIL after 2 mo of in vitro 
expansion.  96-98% of the T  cells  stained positive with an 
Ab  recognizing all ~/8+  T  cells,  and  99%  of T  cells  from 
three different TIL hnes stained positive with a mAb defin- 
ing the  V81/JB1/JB2 +  subset  (mAb BTCS1).  TIL stained 
negative for reactivity with  a rnAb detecting the V82 §  T 
cell subset, which is the most frequent ~/8 T  cell population 
in PBL. The majority of the V81/J81 + TIL population also 
coordinately  stained  positive  with  an Ab  recognizing the 
V~/2 +  subset  (or according to  an  alternate  nomenclature, 
V~/9) staining 89% of cells in TIL 1881, 76% of cells in TIL 
3481, and 55% of cells in TIL 7279. The ot]3  + T  cell popu- 
lation represented a minor contaminant of 0.1-2% in indi- 
vidual  TIL cultures.  To  obtain  additional  characterization 
of specific V~/usage  in such V8I + TIL, we evaluated V~r 
usage by RT-PCR  using a primer panel specific for VS/~ 
subset families. All three ~/8 T  cell lines exhibited VSl-spe- 
cific  transcripts  by  RT-PCR  and  common  usage  of the 
V~/1.2, ~/1.8,  and ~/2 chains of the TCR  (data not shown). 
In  Vitro-cultured "y8  + T  Lymphocytes Obtained from Different 
Patients  Express  a  Similar  Pattern  of Expression  of Adhesion 
Molecules.  Positively selected "78 T  cells were analyzed for 
expression  of activation markers  or adhesion molecules by 
flow  cytometry using a  panel  of mAbs listed  in  Table  1. 
Characteristically,  examination of cell surface expression of 
CD8 and CD4 in these TIL lines indicated the presence of 
more  than  one  discrete  ~/8 +  T  cell  population  showing 
high and intermediate level of CD8 expression, as well as a 
population  reproducibly  characterized  by  intermediate 
level  of CD8  concomitant with  CD4  expression  (Fig.  2). 
These ~/B+ TIL lines expressed  a reproducibly similar pat- 
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Figure 1.  Colorectal cancer-derived ~/8 TIL 
exclusively use the VS1 chain and preferentially 
coexpress the V~/2 chain of the TCR. ~/8 § T 
cells (obtained from patients 1881, 3481, and 
7279) were isolated by cell sorting using the 
anti-pan-~/B rnAb5A6.E93, and cultured for 2 
wk in AIM-V medium containing ILl~3/IL-7 
(1,000 IU/ml)  before phenotypic analysis by 
flow cytometry using mAbs recognizing 0tl3 or 
"78 T cell subsets. Positively sorted TIL stained 
for 98% of the cell population positive with an 
anti-pan-~/B TCR mAb or using the V81/J81/ 
J~2-specific  mAb  BTCS-1. The  majority of 
cells expressed the V3'2 chain and stained nega- 
tive for expression of the VB2 chain or the cel3 
TCR. 
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Figure 2.  CD4 and CD8 expression in colorectal cancer 
yg+ TIL. 2t8 positively-sorted TIL (see Fig. 1) were stained 
for CD4 and CD8 expression by flow cytometry. The ma- 
jority  of "y8  + TIL exhibited the  CD8+CD4" phenotype. 
CD4+CD8 + (double positive) y8 TIL were repetitively 
observed in ~/8 TIL lines 3481 and 7279. 
tern of reactivity using mAb specific for activation or adhe- 
sion  molecules  (summarized  in  Table  2),  exhibiting  a 
CDlla-c +,  CD30 +,  CD44 +,  CD45R.A  high,  CD45P,.O 
low, MHC  class II low, IL-2 receptor (TAC) low, CD69 +, 
very  late  Ag  (VLA)  1-6 +,  vitronectin  receptor-,  and  fi- 
bronectin receptor + phenotype. 
Cotorectat Cancer-derived V81 + TIL Exhibit a Similar Pat- 
tern of Cellular Reactivity against Colorectal, Pancreatic, and Re- 
nal  Cell  Cancers Defined by  Cytolysis and  IFN-T  Release. 
`/8 + TIL lines were  evaluated at three  different times dur- 
ing in vitro culture for cytolytic reactivity against a panel of 
target  cancer cell lines  of diverse histological  origin  (com- 
piled in  Fig.  3).  TIL release of IFN-`/in  response to each 
target  was  also  evaluated  for the  three  `/8  TIL lines.  7-d 
LAK cells  (PBL  cultured  in  1,000  IU/ml  IL-2)  served  as 
control  effector cells  and  efficiently  lysed  each  target  cell 
line  (>45% lysis at an E/T  of 30:1)  with the exception  of 
the colorectal cancer cell line HT29 (showing  10% specific 
lysis),  y5  TIL  lines  lysed  the  NK  target  cell  fine  K562 
poorly  (in  the  range  of 8-14%  specific lysis)  and  failed to 
lyse a variety of the LAK/NK-sensitive target cell lines in- 
cluding  Daudi,  CIR,  U937,  Molt-4,  and T2.  EBV-trans- 
formed B  cell targets, as well as mucin-expressing EBV + B 
cell  lines  (C1P,-Mucl,  S-EBV-Mucl)  were  not  lysed by 
`/g  TIL.  Examination  of IFN-~  release  by  individual  ~/8 
TIL lines in response to these target cells revealed no signif- 
icant increase in IFN-`/secretion  compared with the  con- 
stitutive  release  of IFN-`/  in  the  range  of 37-40  pg/ml/ 
16 h  (Fig. 3). 
Of interest, "/8 TIL lines  1881,  3481,  and 7279 lysed the 
colorectal  cancer  cell  line  3481  (obtained  from  patient 
3481)  in  addition  to  four  different  allogeneic  colorectal 
cancer cell lines, with the exception of HT29. Examination 
of TIL release of IFN-`/in response to autologous  (i.e., in 
the  case of the  matched -/8 TIL line 3481  and tumor line 
3481)  and  allogeneic  colorectal  cancer  cell  lines  revealed 
that  all three  `/~ TIL lines  secreted  IFN-`/  in  response  to 
autologous or allogeneic tumor cell fines (~<273 pg/ml/16 h), 
even in the absence of a significant cytolytic response (i.e., 
in the case of the target cell line HT29). These `/8 TIL lines 
did  not  lyse or secrete  significant  levels  of IFN-%  in  re- 
sponse  to  diverse  target  cell  lines,  i.e.,  melanoma,  one 
breast  cancer,  lung  cancer,  or  autologous  (obtained  from 
patient  3481)  or allogeneic fibroblasts.  In contrast,  ~/8 TIL 
lines  1881,  3481,  and 7279  efficiently lysed two pancreatic 
cancer cell lines  (pancreas89  and pancreasQGP-I),  two re- 
nal cell cancer cell fines (P,.C1257 and R.CC1973),  the nor- 
real  human  intestine  explant  culture  line  (passage  1, 
CRL7136;  ATCC),  and  to a  lesser extent,  the Wilms tu- 
mor cell fine SKNEP-1.  However,  these  `/8 TIL did  not 
lyse two additional squamous cell cancer cell lines  (PCI-13 
and  PCI-50,  data  not  shown).  Target-specific  release  of 
IFN-`/release by V81 + T  cells in response to these targets 
was  not  significant.  Of note,  despite  some  minimal  cyto- 
toxic `/~ TIL responses against K562,  we could not detect 
significantly elevated IFN-`/secretion by `/8 TIL stimulated 
by K562  (in  the  range  of 40  pg/ml/16  h  compared with 
~<260 pg/mI IFN-gr release in response to colorectal cancer 
stimulator  cells).  ~/8  TIE did  not  proliferate specifically in 
response to in vitro stimulation with colorectal cancer cells 
or tumors of alternate histologies (data not shown). 
The  T8  TCR,  the ,82 and ,87 Integrin Chains and the Fi- 
bronectin Receptor  Are Involved in y6+ T Cell-mediated Cytoly- 
sis of Tumor Targets.  To evaluate the functional  impact of 
cell  surface  molecules  on  cytolytic  `/8  T  cell  (colorectal 
cancer cell line  3481)  recognition  of target cells, we incu- 
bated each `/8 TIL line with Abs directed against the  (pan- 
`/8) TCR., V51 + TCR,  V82 + TCP,., the HFR, the  HVR, 
or  the  [32  or  [37  integrin  chains  before  addition  of 51Cr- 
labeled target cells in 4-h cytotoxicity assays. The cytolytic 
T  cell  recognition  of colorectal  cancer cell  line  3481  was 
inhibited  by '-"30% by the anti-pan-`/5  TCR  or the V51/ 
J81/J82-specific  mAbs  (Fig.  4).  TIL 1881  and 3481  (cyto- 
toxic) recognition of tumor 3481  was similarly inhibited by 
35%.  Addition  of mAb directed against V52 did not  affect 
T  cell-mediated lysis. All three `/5 TIL lines showed a di- 
minished cytotoxic T  cell response ifpreincubated with an- 
tiserum specific for the fibronectin receptor (~<59% inhibi- 
tion of specific lysis) but not with antiserum specific for the 
vitronectin receptor. ",/8 T  cell-mediated lysis was inhibited 
by  80%  by an Ab  directed  against  the  [32  integrin  chain, 
and  by  ~<50%  by a  mAb  directed  against  the  [37  integrin 
chain, a component of the intraepithelial lymphocyte (IEL) 
marker.  This was, however, not a  uniform trend since the 
`/5 TIL line  3481  was only inhibited  by ~10%  by an Ab 
directed against CD103  (i.e., [37 chain). 
Colorectal Cancer-derived V6I +  T  Lymphocytes Recognize 
Cell  SuoCace Ags  Shared by  Cotorectal, Pancreatic, and Renal 
Cell Cancer Cell Lines.  `/5 + TIL fines 1881, 3481, and 7279 
appear  to  recognize  both  autologous  and  allogeneic  col- 
1686  V~I + T Cells Recognize Epithelial  Tumor Cells Table  2.  Phenotypic Analysis  ofT8  + TIL: Activation Markers 
and Adhesion Molecules 
Percent positive-staining  ~/8 TIL  ~/8 TIL  ~/5 TIL 
cells for:  1881  3481  7279 
% 
CD2  98  97  98 
CD3  99  99  99 
CD1 la  99  99  99 
CD 1 lb  97  97  98 
CD11c  84  80  74 
CD25 (TAC)  2  2  2 
CD30  92  82  77 
CD44  90  86  96 
CD45KA  91  94  69 
CD45R.O  14  43  36 
HLA-D1L  15  6  6 
CD69  95  96  95 
CD94  0  23  7 
ICAM-1  95  90  95 
ICAM-2  99  95  96 
CD80  4  8  4 
CD86  24  34  36 
VLA-1  96  95  97 
VLA-2  95  93  93 
VLA-3  31  19  14 
VLA-4  70  98  98 
VLA-5  99  93  93 
VLA-6  43  60  65 
E-Selectin  0  0  0 
L-Select-in  0  0  0 
131-integrin chain  99  99  99 
132-integrin chain  99  99  99 
[33-integfin chain  2  2  1 
137-integrin chain  95  92  99 
cxv  10  8  2 
Ixv[33  2  2  1 
0Lv~3/~5 (HVR)  1  1  1 
cxv[55  2  2  1 
0r  (HFR)  98  95  99 
Positive sorted ~/8  § T cells, analyzed by flow cytometry for expression 
of activation  markers,  exhibited a similar phenotype in three different 
experiments at  various  time points. Viable  lymphocytes  were  gated 
based on size (FSC) and granularity  (SSC) criteria, and data were col- 
lected  for 5,000  cells as determined by forward  light scatter intensity 
using Lysis II software on a FACScan  |  Results are reported as percent 
of cells staining positive for a given marker. 
orectal  cancer  cell lines,  pancreatic  cancer,  and  renal cell 
cancer (Fig. 3). However,  these ~/B T  cell effector cells also 
recognize (to comparably lesser extent) the erythroleukemia 
cell hne K562 and early passage cells derived from "normal 
n. 
k- 
Fibroblasts 
Intestine 
RC 1257 
RC 1973 
BT20 
SKNEP1 
Panc.QGP 
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Figure  3.  Similar target cell recognition pattern ofVB1 + TIL as mea- 
sured by cytotoxicity  and IFN-~/ release. Colorectal  cancer target  cell 
lines and cell hnes of alternate histology were tested for ~B T cell recogni- 
tion using a standard 4-h StCr-release assay or using a 16-h IFN-~/release 
assay as described in Materials and Methods. Ikesults obtained from three 
individual ~/8 TIL lines (1881, 3481, and 7279) are expressed as the mean +- 
SD of  percent specific lysis or IFN-~/release in response to individual tar- 
gets. These  ~8 TIL hnes preferentially lyse colorectal cancer  (CC)  cell 
hnes, the human intestinal cell explant CRL7186,  pancreatic (Pane.), and 
renal cell cancer (RC) cell lines. Tumors of alternate origin were not lysed 
significantly, including  two head and neck squamous cell cancer cell lines, 
allogeneic fibroblasts (data not shown), or autologous fibroblasts (obtained 
from patient  3481). IFN-~/ release by ~/8 TIL is reported  as pg/ml/106 
cells/16 h. E/T =  5:1. 
intestine" (explant culture CRL7136, HS186.INT; ATCC). 
We performed cold target inhibition assays using the SlCr- 
labeled aUogeneic colorectal cancer cell line SW480 and a 
panel of nonlabeled target cell lines as competitive inhibitors 
in order to  evaluate the  commonality of hgands expressed 
on these target cells. Cold targets were admixed with 51Cr- 
labeled SW480 targets at 30:1, 10:1, and 3:1  (cold/hot tar- 
get ratios) as indicated (Fig. 5) with two ~/8 TIL lines (1881 
and 7279)  evaluated as effector cells. Both ~/8 TIL lines ef- 
ficiently lysed the target cell hne SW480 in the absence of 
cold target inhibitors. Recognition of SW480 targets by TIL 
effector cells was effectively inhibited by cold targets includ- 
ing the colorectal cancer cell lines SW480 and DLD-1,  and 
pancreatic cancer (pancreas89), renal cell cancer (RC1257), 
1687  Maeurer et al. Figure 4.  ~/8 T[L cell recognition can 
be blocked by Abs directed against  the 
[32  or [37 integrin chains,  or with Abs 
directed against the fibronectin receptor. 
~t~ TIL lines were incubated at 4~  for 
30 rain with Abs against the TCR (anti- 
pan TS, 5TCSt-V~t  and V~2), anti-[32 
(CDI8),  or  -[37  (CDI03) integrin 
chains,  or with Abs directed against the 
human  vitronectin av63(HVR  )  or  fi- 
bronectin e~s[31 (HFR) receptor,  or  in 
medium alone.  After washing these ~+ 
effector T  cells in AIM-V, SlCr-labeled 
colorectal cancer cells (CC 3481, autol- 
ogous to "~  TIL 3481) were added to 
effector cells  and a  standard 4-h S~Cr- 
release assay was performed. Evaluation 
oft cell reactivity without blocking Abs 
(i.e.,  incubation in  medium  alone)  re- 
vealed that ~5 TIL line 1881 lysed  the 
CC 3481 line to a level of 35%, 3481 ~8 
TIL to a level of 30%, and "y8 7279 ex- 
hibited 43% specific lysis of CC 3481  at 
an E/T ratio of 10:1. Kesults are reported as percent inhibition of specific lysis of control CC 3481 (no Ab) by 3'8 TIL. Preincubation of ~/~ TIL with rel- 
evant anti-TCR Abs reduced CC 3481-specific recognition in the range of 30-35%.  Killing of CC 3481 by ~/8 TIL could also be inhibited using Abs di- 
rected against the [32 and the 67 integrin chains, and with Abs directed against the fibronectin receptor (HFR). In contrast, Abs against the vitronectin re- 
ceptor (HVR), or nonrelevant control IgG, did not efficiendy block ~  T cell-mediated lysis. Incubation of target cells with these mAbs or with mAbs 
directed against MHC class I or II molecules did not result in significant inhibition of target cell cytolysis (data not shown). 
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Figure 5.  V81 + TIL lines recognize common target anUgens expressed 
by tumor cells of epithelial  origin. SlCr labeled SW480 cells (HOT TAR- 
GETS) were  seeded  in  96-well plates  and  (non~lCr-labeled,  COLD 
and  the  erythroleukemia  K562  cell  lines.  In  contrast,  cy- 
tolytic  ~/8  T  cell  recognition  of SlCr-labeled  SW480  cells 
was  only  marginally  inhibited by  cold  targets  such  as  the 
Burkitt  lymphoma  cell  hne  Daudi,  or  cells  derived  from 
normal intestine (CRL7136,  HS186.INT;  ATCC). 
TCR  V~I  Transcripts in  T8  TIL Lines  1881,  3481,  and 
7279.  To  assess potential preferential usage  of V81  tran- 
scripts by individual ~/~ T  cell lines (which apparently rec- 
ognize shared tumor Ags), we extracted mRNA  from each 
TIL hne,  reverse transcribed it into cDNA,  and used V81- 
specific  PCR  primers  (spanning the  V8I  segment  to  the 
constant region of the TCR)  to amplify V81-specific prod- 
ucts;  we subcloned the  PCR  product  and sequenced  8-10 
individual  clones  from  each  TIL  hne  (Fig.  6).  Each  sub- 
cloned PCR  product showed  the TCR  V81  region paired 
exclusively with J81.72%  (20/28)  of TCR  transcripts were 
in frame  and showed  high  diversity in  the  CDR3  region. 
TCR  usage  of the  D83  segment  (20/20)  compared  with 
TARGETS) single cell suspension of the cell lines K562, Daudi, the renal 
cell cancer cell hne lkC1257, the pancreatic cancer cell line panc89, the 
colorectal  cancer cell lines SW480 and DLD-1,  or the human intestinal 
cell explant culture CRL7186 were added concomitantly at various con- 
centrations resulting in 3:1,  10:1, and 30:1  cold/hot target cell ratios. ~/g 
TIL lines 1881 or 7279 were then added to individual assay wells. The ef- 
fector/(hot) target ratio was  10:1 and a 4-h SlCr-release  assay was per- 
formed. ~/5 TIL 1881 exhibited 35%, and ~/8 TIL 7279 30% specific lysis 
of CC 3481 target cells in the absence of cold targets. "y~ TIL recognition 
of (hot) SW480 cells could be inhibited by cold CC SW480,  CC DLD1 
targets,  by the renal cell cancer line KC1257,  the pancreatic cancer cell 
hne panc89, and by K562.  In contrast,  unlabeled Daudi cell targets  did 
not interfere significantly with CC SW480 target cell recognition by "y8 
TIL lines. 
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 the D~2 segment (9/20);  2/20 cDNA clones used the D81 
segment. Nucleotide  sequences assigned to the D81  or the 
D82  regions  were  typically  shorter,  compared  with  seg- 
ments used by D~3.  N/P  region nucleotides  were remark- 
ably long (~<29 bp in cDNA clone 1881-10).  Fig. 7 depicts 
the predicted amino acid sequences encoded by each indi- 
vidual  cDNA  clone.  We  noted  that  in  6/20  TCR  se- 
quences  (3' to the Dg3 segment, NP region), a hydropho- 
bic  aromatic  tyrosine  (Y),  and  in  (different)  8/20 TCR 
sequences,  a hydrophilic,  aliphatic leucine  (L) residue were 
encoded.  The  amino  acid  residue  was  in  some  cDNA 
clones generated by basepairs provided by the V region and 
the N/P  region,  and in other cDNA clones from basepairs 
in the N/P region alone, 3' to the V81 chain of the TCR. 
TCR Repertoire in Colorectal Cancer.  The  V81 +  T  cell 
population has been previously shown to represent the pre- 
dominant T  cell subset observed in normal human intestine 
(5-8).  Since we did not have normal mucosa or PBL avail- 
able from patients  1881,  3481,  and 7279,  we could not di- 
rectly address  whether  the  mRNA  transcripts  detected  in 
"/~ TIL were  also present in normal colonic  mucosa adja- 
cent  to  colon  cancer  or  in  PBL  from  these  patients.  The 
three "/8 TIL lines showed a preferential usage of the V"/2, 
V"/1.2,  and V"/1.8  TCR  segments  (as determined  by RT- 
PCR),  which were also exclusively identified in the freshly 
collected  tumor  samples  obtained  from  these  patients, 
thereby exluding potential in vitro artefacts associated with 
preferential  T  cell  subset  expansion  (data  not  shown).  To 
test for TCP, V~/V"/usage in matched (primary) colon ad- 
enocarcinoma  samples and  in  tumor-free  (distal  or proxi- 
mal  to  the  tumor)  adjacent  mucosa,  we  extracted  RNA 
from freshly collected  tumor/normal  mucosa  samples  ob- 
tained from seven additional patients with primary colorec- 
tal cancer, mP,  NA was reverse transcribed into cDNA and 
tested for TCP, "/or ~ transcripts by RT-PCR  as described 
in  Materials  and  Methods.  Specific  PCR  products  were 
validated  by Southern  blot  analysis  using  internal  primers 
for individual TCR  ~/or 8 transcripts (data not shown). 5/7 
adenocarcinoma  samples  exclusively  expressed  VM  tran- 
scripts, whereas 2/7 adenocarcinoma samples showed addi- 
tional V~2 transcripts, which were also found in 7/7 tumor 
proximal/distal normal mucosa samples (Table 3). 2/7 ade- 
nocarcinoma  samples exclusively expressed the  TCP, '/1.2 
and '/2 transcripts,  and 2/7 cancer samples expressed addi- 
tionally  V~/1.8  transcripts  (identical  to  the  TCR  ~  usage 
pattern in '/$ TIL lines described above). 3/7 cancer speci- 
mens  expressed  the  same  V'/  mRNA  expression  pattern 
and  additionally  expressed V'/3 mRNA.  All seven normal 
(matched)  mucosa specimens showed typical V81  and V82 
mP,  NA transcripts and predominantly V'/1.2, '/1.8, ~/2, "/3, 
and, in two specimens, V~1.4 mRNA,  expression.  In con- 
trast,  the matched adjacent  tumor tissue revealed exclusive 
expression  of V81  and  V"/1.2,  V"/1.8,  and  V"/2  mRNA 
(Table 3). Restricted Vgl/V"/1.2,  V"/1.8, V"/2 mRNA  ex- 
pression patterns  were  also  obtained  upon  examination  of 
25 primary colorectal  cancer specimens and  15  colon ade- 
nocarcinomas metastatic to liver (our unpublished  observa- 
tions). 
CLONE  V delta  1  N/P;, DI; N/P; D2; N/P; D3; N/P  J delta  1 
1881-I  L  G  KNLKSYGGAPS  D  K  L 
1881-3  L  G  E  LYVDELGDT  D  K  L 
1881-5  L  G  E  HRA  FLQIKGVGDTVKGRQV  D  K  L 
1881-7  L  G  E  LDK  PPAGFTGT  K  L 
1881-8  L  G  E  LDGVRYVRGQY  K  L 
1881-10  L  V  Q  I  S  S  P  S K  S HRR  SPRTLGEGTT  D  K  L 
1881-11  L  G  GWG  I  Ru  T  D  K  L 
3481-2  L  6  I  L  F  S  R W G A  Y  T  D  K  L 
3481-4  L  G  DLL  RAGGYGGY  T  D  K  L 
3481-7  L  G  E  LF  HWGTNRW  T  D  K  L 
3481-AB  L  G  DNP  AF  HVVG  PRS  L 
3481-AE  L  G  E  L  F  R  S  R V  P  D  K  L 
7Z79-2  L  G  DSL  RSGGRG  K  L 
7279-3  L  G  E  PWR  A  RWGI  LT  T  D  K  L 
7279-4  L  G  NP  P  F  LPLLGF  T  D  K  L 
7279-5  L  G  E  RQATRLRGYAD  T  D  K  L 
7279-10  L  G  E  HRPSYNWGLKY  T  D  K  L 
7279-11  L  G  GF  RYWGIAGA  K  L 
7279-AA  L  G  PTDLRGGPLY  K  L 
7279-AC  L  G  E  P  P  E  P  R  G  I  T  P GV  O  K  L 
1690  Vgl * T Cells Recognize Epithelial  Tumor Cells 
Figure  7.  Predicted junctional  amino  acid se- 
quences encoded by VSI  transcripts from antitu- 
rnor-reacdve "y~+TIL Individual cDNA clone des- 
ignations correspond to those in Fig. 6. Amino acid 
sequences are reported using the single letter code. 
Note that s/20 cDNA clones exhibit the amino acid 
L in the N/P region 3' to the Vgl region and 6/20 
cDNA clones exhibit the amino acid Y generated 
by the  N/P  region 3'  to the  D~3 segment. Se- 
quence data are available from Genbank/EMBL/ 
DDBJ under accession numbers U30189-U30208. Discussion 
We  have  succcessfully  expanded  three  individual  col- 
orectal cancer-derived ~/8 + T  cell lines by in vitro culture 
using IL-113 and IL-7. This strategy was based on previous 
observations  (39)  that  a  combination  of IL-113  and  IL-7 
promotes  the  preferential  outgrowth  of peritoneal  ~8  T 
cells  from Listeria  monocytogenes-infected  mice.  IL-113 may 
act  directly  on ~/B +  TCR-responsive  T  cells  (39,  40)  or 
IL-l[3-mediated effects may be attributed to initial IL-I[3- 
induced  activation  of dendritic  cells,  which  have  recently 
been shown to be involved in ~/B T  cell activation and ex- 
pansion  (41).  The  IL-113/IL-7-expanded TIL populations 
exhibited  stable  phenotype  and  functional  characteristics 
for 4  mo in culture.  This phenotypic stability may reflect 
an inherent characteristic of the ~/8 T  cell subset examined, 
or may be due to IL-7-mediated effects that have been re- 
ported to sustain Ag-specific (CD4 §  0t[3 T  cells)  in the ab- 
sence  of antigenic  restimulation  for  ~<22  mo  (42).  Cyto- 
kine-mediated effects on cell surface expression of adhesion 
molecules has been well  documented for human NK cells 
that  exhibit  differential  expression  of  CDlla-c,  and 
VLA1-6 cell upon IL-2 stimulation  (43). Alternatively, the 
similar pattern of adhesion molecule expression in ~/B T  cell 
lines  derived  from three  individual  patients  may reflect  a 
tissue-specific  (i.e.,  intestinal)  phenomenon.  For example, 
y8 T  cells isolated from intestinal lymph nodes and Peyer's 
patches appear to express varied levels of CD44 or B7 mol- 
ecules that impact their tissue-biased  homing pattern  (44). 
Synovial  fluid  VB1 + T  cells  from  patients  with juvenile 
rheumatoid arthritis express predominantly the early activa- 
tion marker CD69 and the high molecular isoform of the 
CD45  (CD45RA)  (45),  a  pattern  that  we  similarly  ob- 
served for IL-7-expanded ~/B T  cells in this report. 
The bulk ~/B TIL population obtained from three indi- 
vidual  patients  showed  exclusive  expression  of the  V'81 
TCR  and preferential coexpression of the V~/2 TCR. Ad- 
ditional TCR  ~/transcripts,  including those for the V~/1.2 
and  the  Vyl.8  chains,  were  detected  by  RT-PCR.  Of 
note, a similar restricted pattern of such V~//VB TCR  tran- 
scripts was identified in the majority of colon adenocarci- 
nomas as  compared with  the  adjacent  tumor-free  mucosa 
(showing additional V82, and V~/3,  and V~/1.4 transcripts), 
indicating that this particular ~/8 T  cell population may be 
preferentially enriched at the tumor site. 
~/8 +  T  cells appear to represent  effector cells capable of 
specifically recognizing cancer cells (33--35, 46). All previ- 
ous reports of tumor-reactive ~/8 + T lymphocytes support the 
exclusive expression of the V81 + TCR. VB1 + T  cells spe- 
cifically recognize pancreatic cancer in a MHC-unrestricted 
fashion and proliferate in response to pancreatic cancer cells 
in vitro in sufficient numbers that have prompted some au- 
thors to suggested the clinical implementation of this T  cell 
subset  in the  adoptive  immunotherapy  of pancreatic  can- 
cer.  Additional  reports  have  demonstrated  (non-MHC- 
restricted  and  ~/B  TCR-mediated,  tumor-reactive)  cyto- 
toxic ~/8 T  cell responses in TIL derived from lung cancer 
patients.  This T  cell subset also exclusively used the V81 + 
Table 3.  V3,/V8 TCR mRNA Transcripts Differ in Colorectal Cancer Lesions Compared with Adjacent Tumor-free Mucosa 
and Exhibit a Preferential Usage of V2/1.2,  1.8, 2, and V81 + TCR 
TCR V~/regions  TCR V8 regions 
Sample no.  Histological diagnosis  1.2  1.4  1.8  2  3  4  1  2  3  4  5 
22 
21 
84 
82 
207 
206 
213 
212 
256 
255 
271 
270 
285 
284 
Normal mucosa 
Adenocarcinoma colon 
Normal mucosa 
Adenocarcmoma colon 
Normal mucosa 
Adenocarcinoma colon 
Normal mucosa 
Adenocarcinoma colon 
Normal mucosa 
Adenocarcinoma colon 
Normal mucosa 
Adenocarcinoma colon 
Normal mucosa 
Adenocarcmoma colon 
1.2 
1.2 
1.2 
1.2 
1.2 
1.2 
1.2 
1.2 
1.2 
1.2 
1.4 
1.4 
1.8  2  3  1  2 
1.8  2  1 
1.8  2  3  1  2 
1.8  2  1 
1.8  2  3  1  2 
1.8  2  1 
1.8  2  3  1  2 
1.8  2  3  1  2 
1.8  2  3  1  2 
1.8  2  1 
1.8  2  3  1 
1.8  2  1 
1.8  2  3  1  2 
1.8  2  1 
mRNA was extracted from freshly resected (primary) colorectal cancer specimens and from tumor-free adjacent mucosa harvested 3 cm proximal or 
distal to the tumor lesions. RNA was reverse transcribed into cDNA and tested for V~/VB TCR-specific  mRNA transcripts in individual samples 
by RT-PCR using a primer panel as described in Materials and Methods. Identity of  PCR products was confirmed by using V~- or VB-specific  V-region 
TCR internal oligonucleotides by Southern blot analysis (data not shown). 
1691  Maeurer et al. TCR (33,  34), a finding that has been corroborated for ~8 
T  cell clones obtained from a patient with renal cell cancer 
(35). In this latter study, the majority of  V81 + T  cell clones 
preferentially recognized the autologous renal cell cancer, 
but  additional  V81 +  T  cell clones  from this  patient  also 
lysed allogeneic renal cell cancer hnes  (35).  V81 + T  cells 
have also been identified in a variety of human diseases that 
are  thought  to  have  an  "autoimmune"  etiology (26-31), 
and  have  also  been  identified  in  increased  numbers  in 
Wilms tumors (47) and in the hver of tumor-bearing hosts 
(48).  The V81 + TIL lines generated in our study lyse col- 
orectal, renal cell, and pancreatic cancer cell hnes, an early 
passage  line  of  human  normal  intestine  (CRL7136, 
HS186.INT; ATCC), and to a lesser extent the erythroleu- 
kemia cell line K562.  Our results  confirm previous obser- 
vations  that V81+/V~2  (or "/9) + T  cells  typically do not 
lyse Daudi targets.  Whereas such (V81+V~/2 +) T  cells may 
recognize an Ag expressed on Burkitt's lymphoma cell lines 
(49),  this specificity does not appear to be relevant in our 
study. Based on cold target inhibition assays, our ~/8 TIL 
lines appear to exhibit similar specificities and to recognize 
common target structures expressed by epithelial target cell 
lines  and freshly explanted/cultured intestinal  tissue  (Fig. 
3).  However, "/8  TIL-mediated lysis of SlCr-labeled col- 
orectal cancer cells could not be efficiently inhibited by ex- 
cess unlabeled normal intestinal cells (Fig. 5) suggesting that 
different, distinct target structures expressed by colon can- 
cer and intestinal epithelium may be recognized by ",t8 T 
cells. The observation that a single cell explant culture from 
normal human intestine is also recognized by such 3t8 T cells 
may alternatively suggest that the potential target structures 
for ~/8 T  cell recognition may represent normal "self" (i.e., 
not associated with malignant transformation) Ags with dif- 
ferential  TIL reactivity due  to  differential Ag  expression 
levels on tumors versus normal mucosa.  In any case,  it is 
not yet clear, based on the available  data, whether potential 
autoreactive ~/8+ TIL are functional in vivo  (50,  51),  or 
whether such effects are due to the in vitro expansion ofef- 
fector immune cells in the presence oflL-l[3 and IL-7. Com- 
mon (el[3  + TCR  CTL--defined) Ags  shared by tumors of 
different histologies have recently been reported in murine 
(52)  and in  human  (53)  tumors.  One  may speculate  that 
such  ~/8  CTL-defined  crossreactivity may  reflect  similar 
cellular target stuctures associated with cells ofepithehal or- 
igin.  Of note, antigenically defined (c~[3  +) T  cell reactivity 
observed in human  cancer (melanoma  [54]  and renal cell 
cancer  [53])  supports  the  concept that  antitumor cellular 
immunity,  in fact, represents an autoimmune  response,  a 
finding that may be equally apphcable to antitumor-reac- 
tive ~/8 T  cells. 
CD1 has been reported to be expressed by intestinal cells 
(14,  55)  and may serve as  a potential target structure for 
certain ~/8 T cells. In mice, the nonclassical Tla Ag, also ex- 
pressed in the intestine (15),  may be recognized by CD8 § 
intestinal  Vy5  +  T  cells  (15,  16).  mAbs  directed  against 
MHC class I (w6/32) or II DR (mAb L243), or mAbs rec- 
ognizing CDla or CDlc were not able to block ~/8 T  cell- 
mediated cytotoxicity of target cell lines (data not shown). 
Whereas this suggests  that ~/8 + T  cell recognition of autol- 
ogous  or  allogeneic  cancer cell lines  is  not  restricted by 
MHC class I or II, the inability ofanti-CD1 mAbs to block 
~,t8 T cell reactivity may not be informative because of  inef- 
ficient blocking of relevant determinants.  Examination of 
target cell surface expression ofCD1 Ags revealed that only 
the  cell  line  Molt-4,  not  recognized  by  V81 +  T  cells, 
stained positive for CD1  (data not shown). 
Murine V~/3  + T  cells  (dendritic epidermal T  cells) spe- 
cifically recognize keratinocytes (56).  It is possible that hu- 
man V81 + T  cells recognize cells of epithelial origin in a 
tissue-specific fashion and react against  target structures in- 
duced by stress (i.e., in vitro culture) and/or by malignant 
transformation. Potential candidates for target Ags may rep- 
resent HSPs  (13,  19,  20,  57). Anti-breast-cancer directed 
y8 T  cell responses are augmented by transfecting breast 
tumor cells with the 27-kD HSP protein (58), suggesting a 
role for HSP expression in ~/8 T  cell recognition of solid 
tumors. A  strong correlation between cell surface expres- 
sion of liSP 72 and the 67-kD high affinity laminin recep- 
tor in human lung cancer and the outgrowth ofantitumor- 
directed cytotoxic ~/8 T cells (59) has also been noted, grp 75 
has also been suggested to present tumor-specific Ags (pre- 
sumably in the form ofpeptides) to ~/8 T  cells (57). How- 
ever,  we  were  unable  to  inhibit  T  cell reactivity with  a 
panel of anti-HSP Abs,  a finding that either supports the 
lack of involvement of the specific Ag in ~/8 T  cell-medi- 
ated reactivity or reflects the inability of a given mAb  to 
block a functional epitope present on the  indicated HSP 
(data not shown ). To correlate HSP expression on individ- 
ual target cells with cytolytic ~/8 + T  cell reactivity or spe- 
cific  IFN-~/  release,  we  examined  target  cell surface  ex- 
presssion of several well-characterized HSP subsets (including 
HSP 60, 68, 70, 72, 73, and 75; see Table 1) by flow cy- 
tometry. In summary, all target cell lines tested negative for 
HSP 60, 68, 70, and 75 expression and showed variable cell 
surface staining using mAbs directed against  HSP 72 or 73 
comparably high expression of HSP 72 or 73 (our unpub- 
lished observations). Target cell lines exhibiting compara- 
bly high expression of liSP 72 or 73 (e.g., Daudi, or I 937) 
were not recognized by ",t8 T  cells (Fig. 3). In contrast, the 
human explant culture CRL7136,  HS185.INT from nor- 
real human intestine lacked HSP 72/73 cell surface expres- 
sion,  but  provided target structures  recognized by ~/8  T 
cells. Based on these data,  we could not identify a positive 
correlation of liSP 72 and 73 cell surface expression and ~/8 
T  cell recognition. However, the cell surface density of in- 
dividual HSP subsets  relevant for ~/8 T  cell recognition, as 
well as potential peptides presented by such alternate Ag- 
presenting molecules, are poorly defined. A  more detailed 
examination of  individual intracellular and cell surface fam- 
ily HSP protein expression in targets recognized by human 
intestinal  ~8  T  cells  may  aid  clarification  of the  role  of 
HSPs as candidate target structures. 
Of note,  four mAbs  were able to partially block ~5  T 
cell recognition of  sensitive target cells: Abs directed against 
the TCR, against  the [32 or [37 integrin chains, or an Ab 
against  the HFR receptor. Cellular interactions with fibro- 
1692  V~I + T Cells Recognize Epithelial Tumor Cells nectin have been shown  to  induce  phosphorylation of a 
120-kD protein on T  cells and HFP,.-mediated "costimula- 
tion" may augment T  cell cytotoxicity induced by TCR 
stimulation  (60).  Fibronectin-associated T  cell stimulation 
may therefore facilitate TCR restricted effector cell func- 
tions  (e.g.,  granzyme release),  or it may lower the signal 
threshold required for optimal T  cell stimulation (60, 61). 
Blockade of  the fibronectin receptor on ~  T cells may there- 
fore interfere with ~/~ T  cell stimulation.  Fibronectin also 
appears to be involved in ot4/137-mediated adhesion of T 
cells to the vascular cell adhesion molecule 1 (VCAM-1), or 
to mucosal addressin cell adhesion molecule 1 (MADCAM-1) 
(62).  Interaction  of 137  with  fibronectin,  MADCAM-1, 
and VCAM-1 involves different, functionally distinct deter- 
minants on the 137 integrin molecule (62). Inhibition of cyto- 
toxic y5 T  cell responses with an Ab directed against  the 
137 integrin chain may reflect the importance of 137 integrin 
hgands (i.e., MADCAM, fibronectin, etc.) expressed by tu- 
mor cells of epithehal origin. 
It should be noted that differences in ~/~ T  cell responses 
to individual targets as measured by cytotoxicity and IFN-y 
release may be attributed to the presence of more than one 
discrete effector T  cell population as defined by differential 
cell surface expression of CD8 and CD4 (Fig. 2). CD8 ap- 
pears to be preferentially expressed on V~I §  T  cells,  pre- 
dominantly in  the  form  of a  CD8  ot  chain homodimer, 
which has been shown to be inducible by various cytokines 
(e.g., IL-4; 63-65). The effects oflL-113 or IL-7 cell surface 
expression on CD8  chains has  not been evaluated to this 
end and awaits further clarification. CD8  acts  as an adhe- 
sion molecule for et13 TCR + T  cells and as a signal-trans- 
ducing molecule. The function of CD8 on intestinal "y~ T 
cells remains elusive, since:  (a) CD8 expression appears to 
be  rapidly  induced  after  tissue  homing,  suggesting  that 
CD8  expression may not be correlated with conventional 
Ag-driven activation occurring in MHC  class I-restricted 
ot13  + T  cells (66); and (b) target cell recognition by V~I + T 
cell  clones  appears  not  to  be  affected by  CD8  blockade 
(67).  Additionally, direct cloning of freshly isolated CD4 + 
TCP, y~+ T  cells indicated that VS1 + T  cells may also ex- 
press CD4 in vivo. It is interesting to note that such CD4 + 
~/~ T  cells have been characterized to lack cytolytic func- 
tions,  but to  secrete high levels of cytokines (65).  These 
data may suggest that variations in ~/g T cells responses (e.g., 
different levels of inhibition of target cell lysis using mAbs 
directed against  the ",/8 TC1L; Fig. 4) may reflect the pres- 
ence of such distinct ~/8 T  cell subpopulations defined by 
CD8  and CD4 expression, correlating with different (i.e., 
cytotoxicity and cytokine release)  T  cell effector functions. 
Partial  inhibition  of target  cell recognition by Abs  di- 
rected against the ~/8 TCR, indicates that cytolytic V81 + T 
cell responses are mediated by specific target cell recogni- 
tion  involving the  TCR.  Potential ligands  for ~/5  TCR 
recognition may represent native target cell surface struc- 
tures (11,  12,  17,  19, 20, 21, 68), consolidating the notion 
that the ~/8 T  ceil population may use a fundamentally dif- 
ferent method of target cell recognition as compared with 
that of the MHC-restricted or13 T  cell population. Signifi- 
cant IFN-~ release by three ~/~ TIL hnes derived from co- 
lon cancer patients in response to autologous or allogeneic 
colon cancer cell lines suggests that these ~/~ T  cells may be 
therapeutically  important.  "/8  T  cells  may  therefore  not 
only be useful as effector T  cell subsets  capable of directly 
eradicating  cancer cells  when  adoptively transferred into 
cancer patients, but they also  may be useful in creating a 
"Thl-hke" cytokine milieu within  the  tumor lesion mi- 
croenvironment.  IFN-~/  may  act  directly on  tumor  cells 
e.g., by, for example, increasing cellularly expressed MHC 
products, which serve as restricting molecules for MHC- 
presented peptides capable of being recognized by ot13  + T 
cells. IFN-~/ release in response to cancer may be particu- 
larly important in the case where tumor cells display resis- 
tance to perforin-mediated lysis (e.g., HT29; Fig. 3), which 
may reflect tumor cell overexpression ofCD59, a molecule 
capable  of preventing  perforin  complex  formation  into 
lytic structures on the target cell surface (69). The intimate 
interaction of~/~ and cx13 T  cells has previously been docu- 
mented and it is envisioned that y~+  T  cells may impact 
significantly upon the quality and magnitude of 0t13 T  cell- 
mediated immune responses (70--74). 
In summary,  our results demonstrate that ~/~  TIL hnes 
obtained from colon cancer recognize target structures ex- 
pressed by colon, pancreatic, and by renal cell cancer cells 
in a MHC-unrestricted manner. This particular recognition 
pattern is shared by ~/~ TIL lines obtained from three dif- 
ferent patients,  indicating  that  the  prevalent VS1 +  TCR 
subpopulation may play a role in anti-tumor-directed im- 
munity. Examination of a limited number of TCR  tran- 
scripts  from  colon cancer-derived ~/~  T  cell populations 
expanded in  vitro  supports  the  preferential usage  of the 
V~1/D83/J81  TCR segments that have been reported to 
represent common ~/8 TCR transcripts observed in colon 
biopsies  harvested from normal healthy individuals  (5-8). 
The junctional TCR sequences in ~/8 TIL appear to be di- 
verse, although there was some common usage of certain 
amino acid residues in the N/P regions shared by individ- 
ual  cDNA  clones.  We  believe that  the  exclusive  use  of 
TC1L V81  does not reflect a preferential homing receptor 
for human intestinal ~  T  cells, but rather reflects the in- 
herent useful nature of this particular VDJ  recombination 
in TCR reactive against  certain Ags  expressed by stressed 
intestinal cells or by epithehal cancer cells. 
This work was supported by National Institutes of Health grants CA-59371, CA-56088, CA-57804, and 
AI-23567. W. Walter was supported by SFB 311, A16 DFG, University of Mainz Department of Medical 
Microbiology. 
1693  Maeurer et al. Address correspondence to Dr. Markus ]. Maeurer, Department of Medical Microbiology, University of 
Mainz, Institutshochhaus Augustusplatz,  8.th.fl., D-55101 Mainz, Germany. 
Received  for publication  5June  1995 and in revised form 30January  1996. 
References 
1. Jitsukawa,  S.F.,  F.  Faure,  M.  Lipinski,  F.  Triebel,  and  T. 
Hercend. 1987. A novel subset of human lymphocytes with a 
T cell receptor-',/complex.J. Exp. Med.  166:1192-2001. 
2.  Ciccone, E., S. Ferrini, C. Bottini, O. Viale, I. Prigione, G. 
Pantaleo, G. Tambussi, A. Moretta, and L. Moretta. 1988. A 
monoclonal antibody specific for a common determinant of 
the human T cell receptor ",/8 directly activates CD3 + Wt31- 
lymphocytes to  express their functional program(s). J.  Exp. 
Med.  168:1-11. 
3.  Wu,  Y.-J.,  W.-T.  Tian.,  R.M.  Snider,  C.  Rittershaus,  P. 
Rogers, L. LaManna, and S.H. Ip.  1988.  Signal transduction 
of 78 T  cell antigen receptor with a novel mitogenic anti-8 
antibody.J. Immunol.  141:1476-1482. 
4.  Koning,  F., M.  Knot,  F. Wassenaar, and P.  van den Elsen. 
1989.  Phenotypical heterogeneity among human  T  cell re- 
ceptor 78-expressing clones derived from peripheral blood. 
Eur. J. Immunol.  19:2099-2105. 
5.  Deush, K., F. Luling, K. Reich, M. Classen, H. Wagner, and 
K.  Pfeffer.  1991.  A  major fraction of human  intraepithelial 
lymphocytes simultaneously expresses  the 78 T cell receptor, 
the CD8 accessory molecule and preferentially uses the V81 
gene segment. EurJ. Immunol. 21:1053-1060. 
6.  Lundqvist, C., and H.-L. Mammarstrom. 1993.  T-cell recep- 
tor 78-expressing intraepithelial  lymphocytes are present in nor- 
mal and chronically inflamed gingiva. Immunology. 79:38-46. 
7.  Chowers,  Y.,  W.,  Holtmeier, J.  Harwood,  E.  Morzycka- 
Wroblewska, and M.F. Kagnoff.  1994.  The Vdl  T  cell re- 
ceptor repertoire in human small intestine and colon. J. Exp. 
Med.  180:183-190. 
8.  Wucherpfennig, K.W., Y.J. Liao, M. Prendergast, J. Prender- 
gast,  D.A.  Hailer,  and J.L.  Strominger.  1993.  Human  fetal 
liver 78 T cells predominantly use unusual rearrangements  of  the 
T  cell receptor g and 7 loci expressed in both CD4 § CD8- 
and CD4- CD8- "/8 T cells.J. Exp. Med.  177:425-432. 
9.  Soderstrom,  K.,  A.N.  Bucht,  E.  Halapi,  C,  Lundquist,  A. 
Gronberg, E.  Nilsson, D.  L.M.  Orsini, Y.  van der Wal, F. 
Koning, M.-L. Hammarstrom, and R. Kiessling. 1994.  High 
expression of V78 is a shared feature of human 78 T  cells in 
the epithelium of the gut and in the inflamed synovial tissue. 
J. Immunot.  152:6017--6027. 
10. Rsut, C.J., F. Verreck, H. Vietir, and F. Koning. 1990.  Spe- 
cific recognition of staphylococcal enterotoxin A  by human 
T  cells bearing receptors with the V gamma 9 region. Nature 
(Lond.). 346:572-575. 
11. Tanaka, Y., C. Morita, Y. Tanaka, E. Nieves, M.B. Brenner, 
and B.R.  Bloom.  1995.  Natural and synthetic non-peptide 
antigens  recognized by  human  78  T  cells.  Nature  (Lond.). 
375:155-158. 
12. Sciammas, R., R.M. Johnson, A.I. Sperling, W. Brady, P.S. 
Linsley, P.G.  Spear,  F.W.  Fitch, and J.A. Bluestone.  1994. 
Unique  antigen recognition by a herpesvius-specific TCR- 
~8 cell. J. Immunol.  152:5392-5397. 
13. Fisch, P., M. Malkovsky, S. Kovats, E. Sturm, E. Braakman, 
B.S.  Klein,  S.D.  Voss,  L.W.  Morrissey, R.  DeMars,  W.J. 
Welch et al. 1990.  Recognition by human V79/V82  cells of 
a GroEL homolog on Daudi Burkitt's lymphoma cells. Science 
(Wash. DC). 250:1269-1272. 
14. Balk, S.P., E.C. Ebert, R.L. Blumentthal, F.V. McDermott, 
K.W.  Wucherpfennig,  S.B.  Landau,  and  R.S.  Blumberg. 
1991. Oligoclonal expansion and CD 1 recognition by human 
intestinal intraepithelial lymphocytes. Science (Wash. DC). 253: 
1411-1415. 
15. Morita,  A.,  T.  Takahashi,  E.  Stockert,  E.  Nakayama,  T. 
Tsuji, Y. Matsudaira, L.J. Old, and Y. Obata. 1994.  TL anti- 
gen as a transplantation antigen recognized by TL-restricted 
cytotoxic T cells.J. Exp. Med.  179: 777-785. 
16. Eghtesady, P., C. Panwala, and M. Kronenberg. Recognition 
of the thymus leukemia antigen by intestinal ~/8 T  lympho- 
cytes. Proc. Natl. Acad. Sci. USA. In press. 
17. Havran, W.L., and R. Boismenu. 1994. Activation and func- 
tion of78 T cells. Curr. Opin.  Immunol.  6:442-446. 
18. Davedeau,  F.,  M.A.  Peyrat,  M.M.  Hallet,  J.  Gaschet,  I. 
Houde, R. Vivien, H. Vie, and M. Bonneville. 1993.  Close 
correlation between Daudi and mycobacterial antigen recog- 
nition  by human  78  T  cells  and  expression of V9JPCl",// 
V2DJCS-encoded  T  cell  recptors. J.  Immunol.  151:1214- 
1223. 
19. Kronenberg.  M.  1994.  Antigen recognized by 78  T  cells. 
Curr. Opin.  Immunol.  6:64-71. 
20. Schild,  A.,  N.  Mavaddat,  C.  Litzenberger,  E.W.  Ehrich, 
M.M. Davis, J.A. Bluestone, L. Marls, R.K. Draper, and Y.-H. 
Chien.  1994.  The  nature of major histocompatibility com- 
plex recognition by 78 T cells. Cell. 76:29-37. 
21. Rock, E.P.,  P.R.  Sibbald, M.M.  Davis,  and Y.-H.  Chien. 
1994.  CDR3 length in antigen-specific immune responses. J. 
Exp. Med.  179:323-328. 
22.  Orsini, D.L.M.,  M.  van Gils, Y.M.C.  Kooy, L.  Struyk, G. 
Klein, P. van den Elsen, and F. Koning. 1994. Functional and 
molecular characterization of B-cell responsive V81 + 78  T 
cells. Eur. J. Immunol. 24:3199-3204. 
23. Boullier,  S.,  M.  Cochet,  F.  Poccia,  and  M.-L.  Gougeon. 
1995.  CDR3-independent "/8 V81 § T  cell expansion in the 
peripheral blood of HIV-infected persons. J.  Immunol.  154: 
1418-1431. 
24. Hinz, T., D. Wesch, K. Friese, A. Reckziegel, B. Arden, and 
D. Kabelitz. 1994.  T  cell receptor 78 repertoire in HIV-1- 
infected individuals. Eur.J. Immunol.  24:3044-3049. 
25.  Uyemura, K.,  C.T.  Ho, J.D.  Ohmen,  T.H.  Rea,  and R.L. 
Modlin. 1992.  Selective expansion of V81 + T cells from lep- 
rosy skin lesions. J. Invest. Dermatol. 99:848-852. 
26. Jacobs, M.R., and B.F. Haynes. 1991.  Increase in TCR 3'8 T 
lymphocytes in  synovia  from  rheumatoid  arthritis patients 
with active synovitis.J. Clin. Immunol.  12:130-138. 
27. Bucht, A., K. Soderstrom, T. Hultman,  M.  Uhlen, E. Nils- 
son, R. Kiessling, and A. Gronberg. 1992. T-ceil receptor di- 
versity and activation markers in the V 81  subset of rheuma- 
toid synovial fluid and peripheral blood T lymphocytes. Eur. 
J. ImmunoL 22:657-662. 
28. Hvas, J., J.R.  Oksenberg,  R.  Fernando,  L.  Steinman,  and 
C.C. Bernard.  1993.  Gamma delta T  cell receptor repertoire 
1694  V81 + T Cells Recognize Epithelial Tumor Cells in brain lesion of patients with multiple sclerosis. J.  Neuroim- 
munol. 46:225-245. 
29. Shimonkevitz, R., C. Loburnm, J.A. Burnham, R.S. Murray, 
and B.L. Kotzin. 1993. Clonal expansion of  activated gamma/ 
delta T cells in recent onset mutiple sclerosis. Proc. Natl. Acad. 
Sci. USA. 90:923-927. 
30. Hlstensen,  T.S.,  H.  Scott,  and P.  Brandtzaeg.  1989.  Intra- 
pithelial T  cells of the TCR ~/5 + CD8- and V51/J51 + phe- 
notypes are increased in coefiac disease. Scan.  J. Immunol. 30:65-- 
72. 
31. Trejdosiewicz, L.K., A.  Calabrese, C.J.  Smart, D.J.  Oakes, 
P.D.  Howdle, J.E.  Crabtree,  M.S.  Losowsky, F. Lancaster, 
and A.W. Boylston. 1991. ~/5 T cell receptor-positive cells of 
human gastrointestinal mucosa: occurence and V region gene 
expression in helicobacter pylori-associated gastritis,  coeliac 
disease and inflammatory bowel disease.  Clin. Exp.  Immunol. 
84:440-448. 
32. Moliterno,  R.,  W.  Woan,  C.  Bentlejewski, J.  Qian,  A. 
Zeevi,  S.  Pham,  B.P.  Griffith, and R.J.  Duquesnoy.  1994. 
Heat shock protein-induced T-lymphocytes propagation from 
endomyocardial biopsies in heart transplantation.  J. Heart Lung 
Transplant. 14:329-337. 
33. Zocchi, M.R., M. Ferrarini, and C. Rugarli. 1990.  Selective 
lysis of the autologous tumor by 5TCS1 + "/5 + tumour infil- 
trating lymphocytes from human lung carcinomas. Eur. J. Im- 
munol. 20:2685-2689. 
34.  Zocchi,  M.R.,  M.  Ferrarini, N.  Migone,  and  G.  Casorati. 
1994.  T-cell receptor V ~ gene usage by tumour reactive "y5 
T  lymphocytes infiltrating human  lung cancer. Immunology. 
81:234-239. 
35. Choudhary, A., F. Davodeau, A. Moreau, M.-A. Peyrat, M. 
Bonneville, and F. Joterau. 1995. Selective lysis of autologous 
tumor ceils by recurrent ",/5 tumor-infiltrating lymphocytes 
from renal cell carcinomas.J. Immunol. 154:3932-3940. 
36. Jerome, K.R., N. Domenech, and O.J. Finn. 1993.  Tumor- 
specific cytotoxic T  cell clones from patients with breast and 
pancreatic adenocarcinoma recognize EBV-immortalized B 
cells transfected with polymorphic epithelial mucin comple- 
mentary DNA.J. Immunol. 151:1654-1662. 
37. Elder, E.M., and T.L. Whiteside. 1992.  Processing of tumors 
for vaccine and/or tumor infiltrating lymphocytes. In Manual 
of Clinical Laboratory Immunology. 4th ed. N.R.  Rose, E. 
Conway  de  Macaio, J.L.  Fahey,  H.  Friedman,  and  G.M. 
Penn, editors. American Society for Microbiology, Washing- 
ton, DC. 817-819. 
38. Chomczynski, P.,  and N.  Sacchi.  1987.  Single-step method 
of RNA isolation by acid guanidinium thiocyanate-phenol- 
chloroform extraction. Anal.  Biochem. 162:156--159. 
39. Skeen, M.J., and H.K. Ziegler. 1993.  Intercellular interaction 
and cytokine responsiveness of peritoneal c~[3 and "/5 T  cells 
from listeria-infected mice: Synergistic effects ofinterleukin 1 
and 7 on ",/~ T cells.J. Exp. Med.  178:985-996. 
40. Skeen,  M.J.,  and  H.K.  Ziegler.  1993.  Induction of murine 
peritoneal gamma/delta T  cells and their role in bacterial in- 
fection.J. Exp.  Med. 178:971-984. 
41. Takamizawa, M., F. Fagnoni, A. Mehta-Damani, A. Rivas, 
and E.G. Englman. 1995.  Cellular and molecular basis of hu- 
man ",/5 T  cell activation: role of accessory molecules in allo- 
activation.J. Clin. Invest. 95:296-303. 
42. Lynch, D.H., and R.E. Miller. 1994.  Interleukin 7 promotes 
long-term in vitro growth of anti-tumor cytotoxic T  lym- 
phocytes with  immunotherapeutic  efficacy in vivo. J.  Exp. 
Med.  179:31-42. 
43. Maenpaa, A., J. Jaaslelainen, O. Carpten, M. Patarroyo, and 
T. Timonen. 1993. Expression of integrin and other adhesion 
molecules on NK cells; impact of IL-2 on short- and long- 
term cultures. Int.J.  Cancer. 53:850-855. 
44.  Chao, C.-C., M. Sandor, and M.O. Dailey. 1994. Expression 
and regulation of adhesion molecules by "y~ T cells from lym- 
phoid tissues  and intestinal epithelium. Eur. J.  Immunol. 24: 
3180-3187. 
45. Kjeldsen-Kragh, J.,  A.L. Quale,  O.  Vinje, J.B.  Natvig, and 
O. Forre. 1993. A high proportion of the V delta 1  + synovial 
fluid gamma delta T  cells in juvenile rheumatoid arthritis pa- 
tients  express the  very early activation marker  CD69,  but 
carry the  high  molecular weight  isoform of the  leucocyte 
common antigen CD45RA. Clin. Exp. Immunol. 91:202-211. 
46. Kitayama, J., Y. Atom_i, H. Nagawa, A. Kurado, T. Mutoh, 
M.  Minami, and T. Juji.  1993.  Functional analysis  of TCR 
gamma  delta  +  T  cells  in  tumour-infiltrating  lymphocytes 
(TIL) of human  pancreatic cancer.  Clin.  Exp.  Immunol. 93: 
442-447. 
47.  Nanno, M., H. Seki, G. Mathioudakis, R.  Suzuki, K. Itoh, 
C.G.  Ionnides, S. Suzuki, P.-F. Chen, and C.D. Platsoucas. 
1992.  ~/5 T  cell antigen receptors expressed on tumor-infil- 
trating lymphocytes from patients with solid tumors. Eur. J. 
Immunol. 22:679-687. 
48. Seki,  S.,  T.  Abo,  T.  Masuda,  T.  Ohteki,  A.  Kanno,  K. 
Takeda,  H.  Rikiishi,  ILl. Nagura,  and  K.  Kumagi.  1990. 
Identification of activated T  cell receptor "/~ lymphocytes in 
the liver of tumor-bearing hosts.J.  Clin. Invest. 86:409--415. 
49. Fisch, P., K. Oettel, N. Fudim, J.E. Surfus,  M. Malkowsky, 
and  P.M.  Sondel.  1992.  MHC  unrestricted  cytotoxic and 
proliferative responses of two distinct human ~//~ T  cell sub- 
sets to Daudi cells.J. Immunol. 148:2315-2323. 
50. Ferrick, D.A., L.  Gerrtmell-Hori., B.  Sydora, T.  Mulvania, 
J.M. Penninger, M. Kronenberg, and T.W. Mak. 1994.  Tol- 
erance and self-reactivity in V  gamma 1.1C gamma 4 trans- 
genic mice. Int. Rev. lmmunol.  11:295-304. 
51. Garrett,  T.A.,  M.L.  Delvy,  D.M.  Kennedy,  L.  Lefrancois, 
L.A. Matis, A.L. Dent,  S.M.  Hendrick, and J.A. Bluestone. 
1992.  Mechanisms of self tolerance of"/8 T  cells in epithelial 
tissue.J. Exp. Med. 175:65-72. 
52. Itoh, T.,  W.J.  Storkus,  E.  Gorelik, and M.T.  Lotze.  1994. 
Partial purification of murine tumor-associated peptide epi- 
topes  common  to  histologically distinct tumors,  melanoma 
and sarcoma, that are presented by H-2K  b molecules and rec- 
ognized by CD8 + tumor-infiltrating lymphocytes. J.  Immu- 
nol. 153:1202-1215. 
53. Bernhard,  H.J.  Karbach, T. W61fel,  S.  Stoerkel, C.  Huber, 
J.-H. zum B/ischenfelde, and A. Knuth.  1995.  Human renal 
cell carcinomas and normal kidney cells share antigens recog- 
nized by HLA-A2 restricted cytotoxic T  lymphocyte CTL 
clones. Int. J.  Cancer  59:837-842. 
54. Anichini, A., C. Maccalli, R. Mortarini, S. Salvi, A. Mazzoc- 
chi, P. Squarcina, M. Herlyn, and G. Parmiani. 1993.  Mela- 
noma cells and normal melanocytes share antigens recognized 
by  HLA-A2 restricted cytotoxic T  cell clones from  mela- 
noma patients. J. Exp. Med.  177:265-272. 
55. Faure, F., S. Jitsukawa, C. Miossec, and T. Hercend.  1990. 
CDlc as a target recognition structure for human T lympho- 
cytes: analysis with peripheral blood ~//~ cells. Eur. J.  Immu- 
nol. 20:703-706. 
56.  Havran, W.L., Y.H. Chen, andJ.P. Allison. 1991.  Recogni- 
tion of self antigen by skin-derived T  cells with invariant ~/~ 
antigen receptors. Science (Wash. DC). 52:1430-1432. 
1695  Maeurer et al. 57. Kim, H.T.,  E.L.  Nelson,  C.  Clayberger, M.  Sanjanwala, J. 
Sklar, and A.M. Krensky. 1995.  ~/~ T  cell recognition of tu- 
mor Ig peptide.J. Immunol.  154:1614-1623. 
58. Mahvi, D.M., S.W. Carper, F.K. Storm, S.R. Teal, and P.M. 
Sondel. 1993.  Overexpression of 27-kDa heat-shock protein 
in MCF-7 breast cancer cells:  effects  on lymphocyte-medi- 
ated killing by natural killer and "y8 T  cells.  Cancer ImmunoL 
Immunother.  37:181-186. 
59.  Ferrarini, M., S.M.  Pupa, M.R.  Zocchi, C. Rugarli, and S. 
Menard.  1994.  Distinct pattern  of HSP72  and  monomeric 
laminin receptor expression in human lung cancers infiltrated 
by gamma/delta T lymphocytes. Int. J.  Cancer. 57:486-490. 
60. Gismondi, A., M.  Milella, G. Palmieri, M.  Piccoli, L.  Frati, 
and A. Santoni.  1995.  Stimulation of protein tyrosine phos- 
phorylation by interaction of NK  cells with fibronectin via 
ot4J31 and ot51B1.J. Immunol.  154:3128-3137. 
61. Ostergaard,  H.L,  and  E.A.  Ma.  1995.  Fibronectin induces 
phosphorylation of  a 120 kDa protein and synergizes with the 
T  cell receptor to activated cytotoxic T  cell clones. Eur. J, 
Immunol. 25:252-256. 
62. Andrew,  D.P.,  C.  Berlin,  S.  Honda,  T.  Yoshino,  A.  Ha- 
mann, B. Holzmann, P.J.  Kilshaw, and E.C. Butcher.  1994. 
Distinct but overlapping epitopes are involved in alpha 4 and 
beta 7-mediated adhesion to vascular cell adhesion molecule-l, 
mucosal  addressin-1, fibronectin,  and  lymphocyte aggrega- 
tion.J. Immunol.  153:3847-3861. 
63. Moretta,  A.,  C.  Bottino,  E.  Ciccone,  G.  Tamhussi,  M.C. 
Mingari,  S.  Ferrini,  G.  Casorati,  P.  Varese,  O.  Viale,  N. 
Migone,  and  L.  Moretta.  1988.  Human  peripheral blood 
lymphocytes beating T  cell receptor ~//8:  expression of CD8 
differentiation antigen correlates with the  expression of the 
55-kDa, C3~2-encoded 3~ chain._/.  Exp. Meal. 168:2349-2354. 
64.  Paliard, X., R. de Waal Malefijt, J.E. de Vries, and H. Spits. 
I988.  Interleukin-4  mediates  CD8  induction  on  human 
CD4 + T cell clones. Nature (Lond.).  335:642-644. 
65.  Spits, H.  1991.  Human T  cell receptor ~g+ T  cells. Sem. Im- 
munol.  3:119-129. 
66. Bucy, R.P.,  C.-L. Chen, and M.D.  Cooper.  1991.  Analysis 
of3~8 T  cells in the chicken. Sere.  Immunol.  3:109-117. 
67. Spits,  H.,  X.  Paliard,  V.H.  Engelhard,  and J.E.  de  Vries. 
1990.  Cytotoxic activity and lymphokine production of T 
cell receptor (TCR)-c~J3 + and TCR.-~/~ + cytotoxic T  lym- 
phocyte  (CTL)  clones  recognizing  HLA-A2 and  HLA-A2 
mutants: recognition of TCR-'y~5  CTL clones is affected by 
mutations at positions 152  and  156. J.  [mmunol.  144:4156- 
4162. 
68. Bukowski, J.F., C.T. Morita, Y. Tanaka, B.R. Bloom, M.B. 
Brenner, and H. Band.  1995. V~/2V~2 TCR dependent rec- 
ognition ofnon-peptide antigens and Daudi cells analyzed by 
TCR gene transfer. J. lmmunol.  154:998-1006. 
69. Bjorge, L., C.A. Vedeler, E. Ulvestad, and R. Matre.  1994. 
Expression and  function  of CD59  on  colonic adenocarci- 
noma cells. Eur.J. ImmunoL  24:1597-1603. 
70. Askenaze, P.W., M. Szczepanik, M. Ptak, V. Paliwal, and W. 
Ptak. 1995.  ~/8 T  cells in normal spleen assist immunized ot[3 
T cells in the adoptive transfer of contact sensitivity. Effect of 
Bordatella pertussis,  cyclophosphamide, and antibodies to de- 
terminants on suppressor cells.J, lmmunol.  154:1644-1653. 
71.  Ferrick, D.A., M.D. Schrenzel, T. Mulvania, B. Hsieh, W.G. 
Ferlin, and H. Lepper. 1995. Differential production ofinter- 
feron-~ and interleukin-4 in response to Thl- and Th2-stim- 
ulating pathogens by ~/8 T  cells in vivo. Nature (Lond.).  373: 
255-257. 
72. Dieli, F., G.L. Asherson, G.C. Romano,  G. Sireci, F.  Ger- 
vasi, and A. Salermo. 1994.  IL-4 is essential  for the systemic 
transfer of delayed hypersensitivity by T cell lines. Role ofy/~ 
cells._]. Immunol.  152:2698-2704. 
73. Kaufmann,  S.H.E,  C.  Blum,  and  S.  Yamamoto.  1993. 
Crosstalk between ~x/[3 T  cells and 3~/8 T  cells in vivo: acti- 
vation of or/J3 T-cell responses after "//8  T-cell modulation 
with  the  monoclonal antibody GL3.  Proc. Natl.  Acad.  Sci. 
USA.  90:9620-9624. 
74. Fujihashi K., T. Taguchi, W.K. Aicher, J.R.  McGhee, J.A. 
Bluestone, J.H. Eldridge, and H. Kiyono. 1992.  Immunoreg- 
ulatory functions for routine intraepithelial lymphocytes: ~/g 
T cell receptor (TCR +) T cells abrogate oral tolerance, while 
c~/j3 TCR + T  cells provide B  cell help. J.  Exp.  Med.  175: 
695-707. 
1696  V81 § T Cells Recognize Epithelial Tumor Cells 